Coronary Atherectomy Trial Sees First Patient

A first subject has been enrolled in the ECLIPSE clinical trial, the first to date expressly designed to assess the utility of adjunctive coronary atherectomy for calcific CAD.


Cardiovascular Systems, Inc. developed the Diamondback 360® Coronary OAS (Orbital Atherectomy System), the first and only atherectomy device approved to specifically treat severely calcified coronary arteries. Since FDA approval on October 21, 2013, over 25,000 devices have been used to treat patients with CAD.

In partnership with Cardiovascular Research Foundation (CRF), ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half the participants will receive orbital atherectomy prior to Drug Eluting Stent (DES) implantation, while the other half will receive conventional angioplasty, including specialty balloons, followed by DES implantation. The trial is powered to demonstrate differences in the primary endpoints of post-procedural minimal cross-sectional area (assessed by intravascular imaging in a subset of up to 400 patients) as well as in the clinical outcome of target vessel failure at one year. ECLIPSE will also evaluate key health economic outcomes.

The first subject was treated by Dr. Richard Shlofmitz, interventional cardiologist and the Director of the Department of Cardiology at St. Francis Hospital, Roslyn, NY. Dr. Shlofmitz also treated subjects in CSI’s ORBIT II and COAST clinical studies.

Physician comments

“Severely calcified coronary lesions have continued to grow in complexity while treating coronary artery disease (CAD),” Dr. Shlofmitz said. “The Diamondback 360® Coronary Orbital Atherectomy System provides a novel treatment option for these patients compared to conventional angioplasty. Definitive data from the ECLIPSE clinical trial will guide my treatment approach for these difficult-to-treat patients.”

“Many of us feel that coronary atherectomy is underutilized, particularly given the increasing complexity of lesions and patients seen in current-day interventional practice,” said Dr. Ajay Kirtane, the Director of the Cardiac Catheterization Laboratories at New York-Presbyterian/Columbia University Irving Medical Center, and one of the principal investigators of the ECLIPSE trial. Approximately 12 percent of coronary lesions are calcified, and current estimates suggest that atherectomy is only used in approximately 3 percent of coronary interventions. Dr. Kirtane added, “ECLIPSE is the largest randomized clinical trial to date expressly designed to assess the utility of adjunctive coronary atherectomy for calcific CAD.”

Dr. Philippe Généreux, co-principal investigator of the trial stated,  “Coronary calcification has been shown to increase procedural difficulty and adverse events following conventional percutaneous coronary intervention (PCI). The use of orbital atherectomy has the ability to significantly modify lesion morphology, enabling successful stent delivery to help optimize stent expansion and apposition. This supports why we are randomizing to conventional angioplasty, toward the goal of ultimately improving PCI outcomes. The value of this trial is that it will inform physicians regarding the most effective treatment protocols and strategies for treating patients with calcific CAD.”

Dr Généreux is an interventional cardiologist at Morristown Medical Center, NJ, and the Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center,

Company comments

“Our commitment to clinical rigor continues to be a cornerstone in advancing our leadership in atherectomy,” said Scott Ward, President and CEO of Cardiovascular Systems. “The ECLIPSE trial is another important scientific step in demonstrating that the Diamondback 360® Coronary OAS will broaden physicians’ ability to safely and effectively treat more challenging CAD patients.”

Source: Business Wire



Share your thoughts

Your email address will not be published. Required fields are marked *